![](/img/cover-not-exists.png)
A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) + Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients.
Vo, A., Choi, J., Cisneros, K., Kahwaji, J., Toyoda, M., Bongha, S., Ge, S., Peng, A., Villicana, R., Jordan, S.Volume:
98
Journal:
Transplantation
DOI:
10.1097/00007890-201407151-00320
Date:
July, 2014
File:
PDF, 288 KB
2014